Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.
Mayo Clinic, Rochester, MN.
Gita
G
Thanarajasingam
Mayo Clinic, Rochester, MN.
Eric S
ES
Edell
Mayo Clinic, Rochester, MN.
Svetomir M
SM
Markovic
D000328:Adult; D000402:Airway Obstruction / Q000209:etiology; D000077548:Anaplastic Lymphoma Kinase; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000473:pathology*; D001999:Bronchoscopy; D000077547:Crizotinib; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural; D016399:Lymphoma, T-Cell / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases